

LIST OF ABBREVIATIONS

| Abbreviation | Stands for |
|---------------------|--|
| µg | : Microgram |
| ng | : Nanogram |
| ACL | : Anterior cruciate ligament |
| ADAMTS | : A disintegrin-like and metalloproteinases with thrombospondin motifs |
| AP1 | : Activator protein 1 |
| ATF | : Activating transcription factor |
| Bil | : Bilateral |
| BMI | : Body mass index |
| CCR4 | : Chemokine (C-C motif) receptor 4 |
| COX | : Cyclo-oxygenase |
| CRP | : C-reactive protein |
| DMOAD | : Disease-modifying osteoarthritis drug |
| ECM | : Extracellular matrix |
| ELISA | : Enzyme-linked immunosorbent assay |
| EMA | : European Medicines Agency |
| ERK1/2 | : Extracellular signal-regulated kinases |
| ESR | : Erythrocyte sedimentation rate |
| FAP ∞ | : Fibroblast activation protein ∞ |
| G1cAT-1 | : Galactose-β-1, 3-glucuronosyltransferase I |
| HA | : Hyaluronic acid |
| ICE | : Interleukin-1 beta-converting enzyme |
| IL-1 | : Interleukin-1 |
| IL-1 β | : Interleukin-1 beta |
| IL-18 | : Interleukin-18 |
| IL-1Ra | : Interleukin-1 receptor antagonist |
| IL-1RII | : Type II interleukin-1 decoy receptor |
| IL-1RI | : Type I interleukin-1 decoy receptor |
| i NOS | : Inducible nitric oxide synthetase |
| JNK | : Jun N-terminal kinase |
| KL | : Kellgren-Lawrence grade |

| | |
|--------------------------------|---|
| Lt | : Left |
| MMP | : Matrix metalloproteinases |
| MR | : Modified Release |
| MRI | : Magnetic resonance imaging |
| mRNA | : Messenger ribonucleic acid |
| NF-κB | : Nuclear factor kappa B |
| NO | : Nitric oxide |
| NSAID | : Nonsteroidal anti-inflammatory drug |
| OA | : Osteoarthritis |
| OD | : Optical density |
| ONOO- | : Peroxynitrite |
| PG | : Proteoglycan |
| PKC | : Protein kinase C |
| QFM | : Quadriceps femoris muscle |
| RA | : Rheumatoid arthritis |
| RANTES | : Regulated upon activation normal T cell expressed and presumably secreted |
| ROM | : Range of motion |
| Rt | : Right |
| TGF | : Transforming growth factor |
| TNF-α | : Tumour necrosis factor-alpha |
| u PAR | : Urokinase-type plasminogen activator receptor |
| VAS | : Visual analogue scale |
| VRS | : Verbal rating scale |

LIST OF TABLES

| Tables No. | | Page |
|-------------------|--|-------------|
| (1) | Materials supplied for measurement of IL1 β | 21 |
| (2) | Distribution of cases enrolled in each of the study groups. | 25 |
| (3) | Demographic data of the studied patients. | 26 |
| (4) | Clinical characteristics of knee osteoarthritis in the 3 studied groups. | 28 |
| (5) | Quadriceps muscle power in the 3 studied groups during initial and the two follow up assessment. | 29 |
| (6) | Hamstring muscle power in the 3 studied groups during initial and the two follow up assessment. | 30 |
| (7a) | Range of motion (ROM) of affected knees of the patients in the 3 studied groups during initial and the two follow up assessment. | 31 |
| (7b) | Range of motion of affected knees of the patients in the 3 studied groups during initial and the two follow up assessment. | 32 |
| (8) | Pain visual analogue, pain verbal rating scales and 20 meters fast walking time in the 3 studied groups during initial and 2 follow up assessment. | 34 |
| (9) | Comparison between the 3 studied groups regarding pain VAS, pain VRS and 20 meters fast walking time. | 41 |
| (10) | Comparison between the 3 studied groups regarding quadriceps muscle power at before treatment and 1 and 2 months follow up assessment. | 48 |
| (11) | Comparison between the 3 studied groups regarding hamstring muscle power at before treatment and 1 and 2 months follow up assessment. | 49 |
| (12) | Synovial and serum IL-1 β level of the studied groups at initial and follow up assessment. | 53 |
| (13) | Synovial and serum IL-1 β level in the patients and control group before treatment and 2 months after treatment. | 58 |
| (14) | Frequency of side effects of diclofenac sodium and diacerein | 62 |

LIST OF FIGURES

| Figures No. | | Page |
|-------------|--|------|
| (1) | Standard curve of IL-1 β | 22 |
| (2) | Box plot for median VAS and its range in Group I between before, 1 and 2 months after treatment. | 35 |
| (3) | Box plot for median VAS and its range in Group II between before, 1 and 2 months after treatment | 35 |
| (4) | Box plot for median VAS and its range in Group III between before, 1 and 2 months after treatment. | 36 |
| (5) | Box plot for median VRS and its range in Group I between before, 1 and 2 months after treatment. | 36 |
| (6) | Box plot for median VRS and its range in Group II between before, 1 and 2 months after treatment. | 37 |
| (7) | Box plot for median VRS and its range in Group III between before, 1 and 2 months after treatment. | 37 |
| (8) | Box plot for median 20 meters fast walking time and its range in Group I between before, 1 and 2 months after treatment. | 38 |
| (9) | Box plot for median 20 meters fast walking time and its range in Group II between before, 1 and 2 months after treatment. | 38 |
| (10) | Box plot for median 20 meters fast walking time and its range in Group III between before, 1 and 2 months after treatment. | 39 |
| (11) | Box plot for median difference of VAS between before and 1 month after treatment and its range in 3 different groups of treatment. | 42 |
| (12) | Box plot for median difference of VAS between 1 month and 2 months after treatment and its range in 3 different groups of treatment. | 42 |
| (13) | Box plot for median difference of VAS between before and 2 months after treatment and its range in 3 different groups of treatment. | 43 |
| (14) | Box plot for median difference of VRS between before and 1 month after treatment and its range in 3 different groups of treatment. | 43 |
| (15) | Box plot for median difference of VRS between 1 month and 2 months after treatment and its range in 3 different groups of treatment. | 44 |
| (16) | Box plot for median difference of VRS between before and 2 months after treatment and its range in 3 different groups of treatment. | 44 |
| (17) | Box plot for median difference of 20 meters fast walking time between before and 1 month after treatment and its range in 3 different groups of treatment. | 45 |

| Figures No. | | Page |
|--------------------|--|-------------|
| (18) | Box plot for median difference of 20 meters fast walking time between 1 month and 2 months after treatment and its range in 3 different groups of treatment. | 45 |
| (19) | Box plot for median difference of 20 meters fast walking time between before and 2 months after treatment and its range in 3 different groups of treatment. | 46 |
| (20) | Lateral radiograph of the knee joint showing the patellofemoral articulation | 50 |
| (21) | Radiograph showing the anteroposterior view of the knee joint | 51 |
| (22) | Box plot for median synovial IL-1 β and its range in group I between before, 1 and 2 month after treatment. | 54 |
| (23) | Box plot for median synovial IL-1 β and its range in group III between before, 1 and 2 month after treatment. | 54 |
| (24) | Box plot for median blood IL-1 β and its range in group I between before, 1 and 2 month after treatment. | 55 |
| (25) | Box plot for median blood IL-1 β and its range in group II between before, 1 and 2 month after treatment. | 55 |
| (26) | Box plot for median blood IL-1 β and its range in group III between before, 1 and 2 month after treatment. | 56 |
| (27) | Box plot for median synovial IL-1 β before treatment and its range between the 3 groups of treatment and controls. | 59 |
| (28) | Box plot for median synovial IL-1 β 2 months after treatment and its range between the 3 groups of treatment and controls. | 59 |
| (29) | Box plot for median blood IL-1 β before treatment and its range between the 3 groups of treatment and controls. | 60 |
| (30) | Box plot for median blood IL-1 β 2 months after treatment and its range between the 3 groups of treatment and controls. | 60 |